Stockholm, Sweden — Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) announced that the Company, as part of its initiatives to increase disease awareness about MCT8 deficiency, has participated and informed about MCT8 deficiency, at the following medical conferences during the first quarter of 2023: British Paediatric Neurology Association (BPNA) Annual...
treatment News
PALO ALTO, Calif. — Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria...
DOVER, Del. — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the completion of a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending...
DOVER, Del. — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical...
Tokyo and Cambridge, Mass. — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and...
Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimus WOODCLIFF LAKE, N.J., Jan. 27, 2021 – Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These...
Stealth BioTherapeutics is planning a Phase 2a clinical trial of elamipretide (SS-31) as a treatment for people with vision loss and/or heart disease associated with Friedreich’s ataxia (FA). The company expects to use data from this study — planned to start later this year — in designing a pivotal clinical...
SOUTH SAN FRANCISCO, Calif. — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced it will present two posters on the ELA026 clinical program in secondary hemophagocytic lymphohistiocytosis (sHLH) at the 67th American Society of Hematology (ASH) Annual Meeting...
SOUTH SAN FRANCISCO, Calif. — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that ELA026 has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation (BTD) and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the...
In patients with cystic fibrosis (CF) and Phe508del–gating or Phe508del–residual function genotypes, the use of elexacaftor (ELX)-tezacaftor (TEZ)-ivacaftor (IVA) triple therapy has demonstrated safety and efficacy, conferring additional benefits relative to prior cystic fibrosis transmembrane conductance regulator (CFTR) modulators. These were among the results of research recently published in The New England Journal of...